The main future direction is to determine whether copeptin may be used as a marker that directs the diagnosis toward ischemic stroke, similarly to the use of procalcitonine to direct the diagnosis toward sepsis and NT-proBNP to direct the diagnosis toward cardiac insufficiency (although these markers may also be increased in other pathologies, they have high sensitivity and specificity) [55,56]. This evidence concerns the gene NPPB and heart failure.